Complex Regional Pain Syndrome (CRPS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Complex Regional Pain Syndrome (CRPS) Market Outlook

Thelansis’s “Complex Regional Pain Syndrome (CRPS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Complex Regional Pain Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Complex Regional Pain Syndrome (CRPS) Overview

Complex regional pain syndrome (CRPS), or Sudeck's dystrophy or reflex sympathetic dystrophy, is a painful condition characterized by various symptoms, including pain, sensory disturbances, Sudo- and vasomotor abnormalities, trophic changes, and impaired motor function. CRPS can develop due to different levels or types of tissue damage. In some cases, it has even been observed without any injury, often arising from extended periods of immobilization. Among the most common causes of CRPS is a fracture, while surgery is another frequent trigger. Other injuries or insults that can incite CRPS encompass sprains, contusions, crush injuries, and surgical procedures. CRPS is categorized into two main types: type I, formerly known as reflex sympathetic dystrophy, and type II, previously termed causalgia. Type I occurs without associated nerve trauma, whereas type II arises following known nerve injuries. Additionally, CRPS is further subdivided into "warm" versus "cold" varieties, and sympathetically-maintained (SMP) versus sympathetically-independent (SIP) forms, which can influence both the prognosis and available treatment options. Patients with CRPS receive treatment from a diverse range of medical specialists, including anaesthesiologists, (orthopaedic) surgeons, neurologists, rheumatologists, and rehabilitation centers, due to the multifaceted nature of the condition and its wide array of symptoms. It's important to note that there are currently no medications approved by the Food and Drug Administration (FDA) specifically for treating CRPS. Consequently, treatment protocols frequently require the use of off-label medications. Limitations in available medications could potentially restrict options for both healthcare providers and patients in managing their symptoms. The prognosis of CRPS varies, with instances of spontaneous remission and refractory clinical presentations observed. However, early intervention may lead to improved outcomes. Long-standing CRPS can be associated with complications such as dystonia, cognitive executive dysfunction, adrenal insufficiency, gastroparesis, and irritable bowel syndrome.

• The prevalence of CRPS varied between 7.68 and 27.1 cases per 100,000 population.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: